|
|
 |
|
Viewing report
|
|
|
|
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Spectra Intelligence , April 2006, Pages: 369
In a market currently valued around US$42 billion, cancer chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years according to a new report from biopharma market research publisher, Spectra Intelligence.
“The chemotherapy market is currently the fastest growing in the pharmaceutical industry, driven by the explosion of potential therapeutic targets revealed by the molecular genetic assessments of cancer biology and fuelled by the magnitude of the disease worldwide, which shows every indication of increased incidence and sustained mortality rates over the next decade” says expert report author Dr Sarah Crawford PhD, Associate Professor of Biology and Director of Experimental Chemotherapy at Southern Connecticut State University, USA.
With more than 25 million people affected by cancer globally, and an estimated 5 million people dying each year as a result of cancer, new treatments are clearly needed to curtail these high mortality statistics despite the availability of effective cancer drugs such as Herceptin and Avastin. Dr Crawford cautions however that although there are very exciting and promising novel cancer therapeutics on the horizon with limitless potential, enthusiasm must be tempered by the need to identify those chemotherapy approaches that may have the greatest potential for therapeutic success and suggests that there is a need to distinguish important new entries to the cancer therapeutics market from those therapy approaches that may not fare as well on the world market.
Biopharmaceutical industry analyst Tim Atkinson, who reviewed the report, said “Dr Crawford has provided an exceptionally comprehensive first-rate analysis of our current understanding of cancer biology, cancer treatment approaches, diagnosis and management, and hopes for the future given the complexity and heterogeneity of this devastating disease. The report uniquely highlights the deficiencies and possibilities of cancer research and cancer drug development, which will undoubtedly help to create significant market opportunities and change the landscape for cancer treatments in the future.”
Dr Crawford adds “The world of molecular medicine and biopharmaceuticals has presented great opportunities to discover and develop new pharmacological approaches with prospects for greater therapeutic efficacy and more promising clinical outcomes. Immunotherapies, monoclonal antibodies, new reformulations, and multimodal chemotherapy treatment regimens that combined with an ever-evolving understanding of the intricacies of cancer and the identification of new potential cell targets, will be the some of the new weapons in our fight against cancer”.
This new report from Spectra Intelligence, Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities, provides an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, R&D programs, and innovating companies and products. The reader will benefit from authoritative critical review, market forecasts to 2016, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate research and industrial growth, and create new market opportunities.
Objectives of the Report
The objectives of this report are to provide an in-depth assessment and analysis of the global cancer therapy market. Included in this study are critical analyses of key therapeutic areas, epidemiological, aetiological, and healthcare data, pipeline programs, and innovating companies and products. It is hoped that the reader will benefit from critical review, market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
Research Methodology
The contents of this report are derived from the author’s own research and analysis and other source material, which may comprise the following:
- Company information
- Personal communication
- Trade press articles
- News releases
- Internet-based research
- Library research
- Scientific periodicals
- Product information
- Market analyst data
- Public information datasets
- Conference proceedings
- Medical/pharma associations
WHAT CAN I LEARN FROM THIS REPORT?
- Market potential for each of the novel cancer therapeutics in late stage clinical development
- Which new cancer therapeutics are likely to produce the best clinical results
- Which areas of preclinical drug research are likely to produce successful chemotherapies over the next few years
- The potential global market for newly approved cancer drugs
- The impact of new drugs on the global cancer market
- Which cancer drugs which have received recent US FDA approval
- Which pipeline cancer drugs which are most likely to receive US FDA approval in the near future
- The global market for specific types of cancer drugs
- The most successful biopharmaceutical companies currently engaged in chemotherapy product development
- Anticipated revenues for newly launched cancer drugs
- Sales forecasts for approved chemotherapies to 2016
- The current status of cancer chemotherapy in general and with regard to specific types of cancer
- The major issues involved in the research and development of chemotherapies
- Which types of cancer therapeutics are currently in research and development
REPORT HIGHLIGHTS AND KEY FINDINGS
- The current market for chemotherapies is estimated at US$42 billion and is forecast to increase approximately 17% to US$49 billion by 2012
- Critical assessment of the challenges to the development of better, more efficacious cancer treatments with fewer side effects
- Analysis of the problems associated with the use of traditional cancer therapeutics, eg. drug resistance, lack of clinical efficacy, side effects
- Focused analysis of the global prevalence of cancer: incidence, mortality and survival rates as they relate to new directions in cancer research
- Identification of the major classes of cancer drugs currently in research and development using the newest technologies and genetic approaches
- Highlights the most successful cancer therapeutics that may serve as prototypes for the research and development of more effective drugs
- Market analysis of trends in the cancer biotech industry to 2016
- Concise product review data for the most innovative and productive biopharmaceutical companies
- Assessment of all recent clinical trial data for investigational cancer drugs and prospects for approval by regulatory agencies
- Comparative assessment of new drugs with similar therapeutic targets
- Assessment of the newest clinical approaches to the treatment of cancer
Products Mentioned
- Gardasil (Merck)
- Cervarix (GlaxoSmithKline)
- Sutent – Pfizer
- Sorafenib (BAY43-9006) - Bayer/Onyx
- Panitumamab - Amgen/Abgenix
- Tykerb (Lapatinib)
- Eltrombopag
- Casopitant
- Femara
- PTKZK
- Introgen Therapeutics: Advexin
- United Therapeutics: OvaRex
- GPC Biotech AG: Satraplatin
- Cell Therapeutics: Xyotax
- NeoPharm: LEP-ETU
- Genta Pharmaceuticals: Genasense
- SuperGen: Orathecin 2
- Dendreon: Provenge
- Bayer: Sorafenib
- Iboctadekin
- Vestipitant
- Ispenesib
- Pazopanib
- Relacatib
- Elacridar
- RAD001
- Patupilone
- PKC412
- ST1571
- Gimatecan
- AMN107
- AEE788
- INGN225
- INGN241
- INGN401
- Xinlay (Atrasentan)
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Cancer Chemotherapy: Basic Science to the Clinic
Cancer Therapeutics Markets
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
The Cancer Clock
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Prostate Cancer Therapeutics - Global Strategic Business Report
European Bladder Cancer Therapeutics Markets
Cancer Therapies - Global Strategic Business Report
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Cancer Therapeutics Markets
|
|
|
|
